Cargando…
Personalized management of dyslipidemias in patients with diabetes—it is time for a new approach (2022)
Dyslipidemia in patients with type 2 diabetes (DMT2) is one of the worst controlled worldwide, with only about 1/4 of patients being on the low-density lipoprotein cholesterol (LDL-C) target. There are many reasons of this, including physicians’ inertia, including diabetologists and cardiologists, t...
Autores principales: | Banach, Maciej, Surma, Stanisław, Reiner, Zeljko, Katsiki, Niki, Penson, Peter E., Fras, Zlatko, Sahebkar, Amirhossein, Paneni, Francesco, Rizzo, Manfredi, Kastelein, John |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706947/ https://www.ncbi.nlm.nih.gov/pubmed/36443827 http://dx.doi.org/10.1186/s12933-022-01684-5 |
Ejemplares similares
-
Postmarketing nutrivigilance safety profile: a line of dietary food supplements containing red yeast rice for dyslipidemia
por: Banach, Maciej, et al.
Publicado: (2021) -
Curcumin - The Nutraceutical With Pleiotropic Effects? Which Cardiometabolic Subjects Might Benefit the Most?
por: Surma, Stanisław, et al.
Publicado: (2022) -
Brief recommendations on the management of adult patients with familial hypercholesterolemia during the COVID-19 pandemic
por: Banach, Maciej, et al.
Publicado: (2020) -
Nutrition, Nutraceuticals and Bioactive Compounds in the Prevention and Fight against Inflammation
por: Surma, Stanisław, et al.
Publicado: (2023) -
Effect of fenofibrate on plasma apolipoprotein C-III levels: a systematic review and meta-analysis of randomised placebo-controlled trials
por: Sahebkar, Amirhossein, et al.
Publicado: (2018)